
	Home Site Map Contact Links Medical News

antegren and multiple sclerosis

Antegren Find the Best Deals
Compare Prices on Antegren and More. Get the Best Deal at BottomDollar!
Top-chart Ringtone!
Free music download with only $9.99/month
Octane Tv!
Watch Free Motorized Videos. Drifting, Racing, Crashing Cars, Motorcycles & Hot Girls
Octane Tv!
Watch Free Motorized Videos. Drifting, Racing, Crashing Cars, Motorcycles & Hot Girls
Octane Tv!
Watch Free Motorized Videos. Drifting, Racing, Crashing Cars, Motorcycles & Hot Girls
Blinkx Video Search
World's largest video search engine. Over 26 million hours of video.

antegren and multiple sclerosis
Biogen Idec and Elan Announce Intention to Submit for Approval for Multiple SclerosisBased on One-Year Data

CAMBRIDGE, Mass antegren and multiple sclerosis. & SAN DIEGO & DUBLIN, Ireland--February 18, 2004--BiogenIdec and Elan Corporation, plc today announced that they expect to submit tothe U.S antegren and multiple sclerosis. Food and Drug Administration (FDA) an application for approval of Antegren(natalizumab) as a treatment for multiple sclerosis (MS) antegren and multiple sclerosis. The companies expectto submit the filing mid-year 2004.

The decision to file a Biologics License Application (BLA) was made after discussionswith the FDA of one-year data from the two ongoing two-year Phase III trialsin MS antegren and multiple sclerosis. The companies are committed to completing the two-year trials antegren and multiple sclerosis. To protectthe integrity of the trials, the companies are not disclosing the one-year dataat this time.

Biogen Idec and Elan are collaborating equally on the development of natalizumabfor MS, Crohn's disease, and rheumatoid arthritis.

About the Antegren MS Clinical Trials
The AFFIRM (natalizumab safety and efficacy in relapsing-remitting MS) trialis a two-year, randomized, multi-center, placebo-controlled, double-blind studyof approximately 900 patients, evaluating the ability of natalizumab to slowthe progression of disability in MS and reduce the rate of clinical relapses antegren and multiple sclerosis. The SENTINEL (safety and efficacy of natalizumab in combination with Avonex(Interferon beta-1a)) trial is a two-year, randomized, multi-center, placebo-controlled,double-blind study of approximately 1,200 patients with relapsing-remittingMS, evaluating the effect of the combination of natalizumab and Avonex comparedto treatment with Avonex alone in slowing the progression of disability andreducing the rate of clinical relapses antegren and multiple sclerosis. Both studies have protocols that includeda one-year analysis of the data antegren and multiple sclerosis. The primary endpoints for both Phase III two-yeartrials in MS are based on the Expanded Disability Status Scale (EDSS) and relapserates antegren and multiple sclerosis. The pre-specified primary endpoint of the one-year analysis was relapserates.

About Antegren (natalizumab)
Natalizumab, a humanized monoclonal antibody, is the first alpha-4 antagonistin the new SAM (selective adhesion molecule) inhibitor class antegren and multiple sclerosis. The drug was designedto selectively inhibit immune cells from leaving the bloodstream and to preventthese cells from migrating into chronically inflamed tissue as occurs in a varietyof inflammatory diseases antegren and multiple sclerosis. To date, approximately 2,800 patients have receivednatalizumab in clinical studies antegren and multiple sclerosis. In previous clinical trials, the followingadverse events occurred more commonly with natalizumab when compared to placebo:headache, nausea, abdominal pain, infection, urinary tract infection, pharyngitisand rash antegren and multiple sclerosis. Serious adverse events have included infrequent hypersensitivity-likereactions.

antegren has approved antegren fda antegren or antigrin antegren has approved antegren fda approval antegren therapy antegren and multiple sclerosis antegren therapy antegren logo antegren fda approval antegren updates antegren and the fda potential problems with antegren antegren natalizumab side effects antegren news antegren and administer how to take antegren biogen antegren antegren multiple sclerosis antegren + headaches antegren and administer antegren therapy antegren news antegren antegren price antegren rumors antegren and administer antegren ms antegren updates antegren results potential problems with antegren antegren price antegren fda approval antegren approval antegren ms antegren news side effects antegren side effects antegren antegren cause rise in alt antegren jama antegren and alt antegren ms antegren therapy antegren rumors antegren multiple sclerosis side effects antegren antegren natalizumab side effects antegren side effects antegren rumors how to take antegren antegren and multiple sclerosis antegren and administer biogen antegren crohn antegren side effects new news on antegren side effects antegren antegren multiple sclerosis antegren + headaches antegren has approved antegren has approved fda antegren ruling antegren approval antegren therapy antegren natalizumab side effects antegren logo antegren and alt antegren or antigrin antegren multiple sclerosis

abilify abraxane accolate accupril accutane acetaminophen aciphex aclovate actifed activase actiza actonel actos aczone adacel adalat adderall adipex advair advate agilect albalon albuterol aldomet alesse aleve alimta allegra aloxi alphagan alprazolam altace altocor alvesco amaryl ambien amiodarone amitriptyline amoxicillin androgel angeliq anidulafungin antabuse antegren anusol apidra apokyn arthrotec asacol aspirin atenolol ativan augmentin avandia avapro avastin avelox axid

aantegren and multiple sclerosis anntegren and multiple sclerosis anttegren and multiple sclerosis anteegren and multiple sclerosis anteggren and multiple sclerosis antegrren and multiple sclerosis antegreen and multiple sclerosis antegrenn and multiple sclerosis antegren and multiple sclerosis antegren aand multiple sclerosis antegren annd multiple sclerosis antegren andd multiple sclerosis antegren and multiple sclerosis antegren and mmultiple sclerosis antegren and muultiple sclerosis antegren and mulltiple sclerosis antegren and multtiple sclerosis antegren and multiiple sclerosis antegren and multipple sclerosis antegren and multiplle sclerosis antegren and multiplee sclerosis antegren and multiple sclerosis antegren and multiple ssclerosis antegren and multiple scclerosis antegren and multiple scllerosis antegren and multiple scleerosis antegren and multiple sclerrosis antegren and multiple scleroosis antegren and multiple sclerossis antegren and multiple sclerosiis antegren and multiple sclerosiss ntegren and multiple sclerosis ategren and multiple sclerosis anegren and multiple sclerosis antgren and multiple sclerosis anteren and multiple sclerosis antegen and multiple sclerosis antegrn and multiple sclerosis antegre and multiple sclerosis antegrenand multiple sclerosis antegren nd multiple sclerosis antegren ad multiple sclerosis antegren an multiple sclerosis antegren andmultiple sclerosis antegren and ultiple sclerosis antegren and mltiple sclerosis antegren and mutiple sclerosis antegren and muliple sclerosis antegren and multple sclerosis antegren and multile sclerosis antegren and multipe sclerosis antegren and multipl sclerosis antegren and multiplesclerosis antegren and multiple clerosis antegren and multiple slerosis antegren and multiple scerosis antegren and multiple sclrosis antegren and multiple scleosis antegren and multiple sclersis antegren and multiple sclerois antegren and multiple scleross antegren and multiple sclerosi a ntegren and multiple sclerosis an tegren and multiple sclerosis ant egren and multiple sclerosis ante gren and multiple sclerosis anteg ren and multiple sclerosis antegr en and multiple sclerosis antegre n and multiple sclerosis antegren and multiple sclerosis antegren and multiple sclerosis antegren a nd multiple sclerosis antegren an d multiple sclerosis antegren and multiple sclerosis antegren and multiple sclerosis antegren and m ultiple sclerosis antegren and mu ltiple sclerosis antegren and mul tiple sclerosis antegren and mult iple sclerosis antegren and multi ple sclerosis antegren and multip le sclerosis antegren and multipl e sclerosis antegren and multiple sclerosis antegren and multiple sclerosis antegren and multiple s clerosis antegren and multiple sc lerosis antegren and multiple scl erosis antegren and multiple scle rosis antegren and multiple scler osis antegren and multiple sclero sis antegren and multiple scleros is antegren and multiple sclerosi s antegren and multiple sclerosis nategren and multiple sclerosis atnegren and multiple sclerosis anetgren and multiple sclerosis antgeren and multiple sclerosis antergen and multiple sclerosis antegern and multiple sclerosis antegrne and multiple sclerosis antegre nand multiple sclerosis antegrena nd multiple sclerosis antegren nad multiple sclerosis antegren adn multiple sclerosis antegren an dmultiple sclerosis antegren andm ultiple sclerosis antegren and umltiple sclerosis antegren and mlutiple sclerosis antegren and mutliple sclerosis antegren and mulitple sclerosis antegren and multpile sclerosis antegren and multilpe sclerosis antegren and multipel sclerosis antegren and multipl esclerosis antegren and multiples clerosis antegren and multiple cslerosis antegren and multiple slcerosis antegren and multiple scelrosis antegren and multiple sclreosis antegren and multiple scleorsis antegren and multiple sclersois antegren and multiple scleroiss antegren and multiple sclerossi aantegren and multiple sclerosis theantegren and multiple sclerosis antegren and multiple sclerosis

a b c d e f g h i k l m n o p r s t u v w x z